OCGN - Ocugen Inc

OCGN - Ocugen Inc

https://www.ocugen.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Ocugen Shares Are Trading Higher Monday: What's Going On? - Ocugen ( NASDAQ:OCGN )

Benzinga • 0 minutes ago • score: 0.53

Ocugen signs a licensing agreement granting Kwangdong exclusive Korean rights to OCU400. The agreement includes up to $7.5 million in upfront and milestone payments, plus potential sales milestones and royalties. See the trading strategy with a perfect track record in 2025 [currently 34-0] →

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen ( NASDAQ:OCGN )

Benzinga • 7 hours, 45 minutes ago • score: 0.20

Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

GlobeNewswire • 7 hours, 45 minutes ago • score: 0.20

MALVERN, Pa., Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Ocugen, Inc. ( "Ocugen" or the "Company" ) ( NASDAQ: OCGN ) , a pioneering biotechnology leader in gene therapies for blindness diseases, today executed a licensing agreement with Kwangdong Pharmaceutical, Co., Ltd., ( "Kwangdong" ) one of the ...

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 - Ocugen ( NASDAQ:OCGN )

Benzinga • 1 week, 6 days ago • score: 0.17

MALVERN, Pa., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Ocugen, Inc. ( "Ocugen" or the "Company" ) OCGN, a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate ...

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

GlobeNewswire • 1 week, 6 days ago • score: 0.17

MALVERN, Pa., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Ocugen, Inc. ( "Ocugen" or the "Company" ) ( NASDAQ: OCGN ) , a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.

52W High

$1.29

52W Low

$0.52

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

4.16

Valuation

Fair

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

15.22

EV/EBITDA (<8 favorable)

-1.95

EV/Revenue (<3 favorable)

68.89

P/S (TTM) (<3 favorable)

67.66

P/B (<3 favorable)

105.40

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

1.49%

Institutions (25–75% balanced)

16.64%

Shares Outstanding

312,305,000

Float

287,938,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

4,754,000

Gross Profit (TTM)

-29,576,000

EPS (TTM)

-0.19

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-10.05%

ROE (TTM) (>15% strong)

-5.70%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.20

Momentum

Bearish momentum

Value

0.0102

Previous

0.0075

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025